Grenda Ryszard, Webb Nicholas J A
Department of Nephrology, Kidney Transplantation and Hypertension, The Children's Memorial Health Institute, Warsaw, Poland.
Pediatr Transplant. 2010 Dec;14(8):961-7. doi: 10.1111/j.1399-3046.2010.01403.x. Epub 2010 Sep 28.
Clinically important adverse events associated with the use of corticosteroids post-transplantation include hypertension, dyslipidemia, impaired glucose metabolism (including diabetes mellitus), growth retardation, bone fractures, and cosmetic problems. Over recent years, a number of studies have investigated the effect of minimizing exposure to corticosteroids in post-transplant immunosuppression protocols in both adults and children. In pediatric patients, several different approaches have been evaluated, including late steroid withdrawal, early steroid withdrawal, and complete steroid avoidance with or without poly- or monoclonal antibody induction and a variety of maintenance immunosuppressants. This manuscript reviews the key studies and documents the specific clinical benefits associated with steroid minimization. The development of PTLD and bone marrow suppression has been a major safety concern in some of these studies. These studies and other adverse effects are discussed.
移植后使用皮质类固醇相关的具有临床重要性的不良事件包括高血压、血脂异常、糖代谢受损(包括糖尿病)、生长发育迟缓、骨折和外观问题。近年来,一些研究调查了在成人和儿童移植后免疫抑制方案中尽量减少皮质类固醇暴露的效果。在儿科患者中,已评估了几种不同方法,包括晚期停用类固醇、早期停用类固醇以及在有或没有多克隆或单克隆抗体诱导和多种维持性免疫抑制剂的情况下完全避免使用类固醇。本手稿回顾了关键研究,并记录了与类固醇最小化相关的具体临床益处。在其中一些研究中,移植后淋巴增殖性疾病(PTLD)和骨髓抑制的发生一直是主要的安全问题。本文将讨论这些研究及其他不良反应。